Edoxaban Suppliers & Bulk Manufacturers
Available Forms: Tablets
Available Strengths: 15 mg, 30 mg, 60 mg
Reference Brands: Savaysa (USA), Lixiana (EU)
Category:
Heart Disorder
Edoxaban is available in Tablets
and strengths such as 15 mg, 30 mg, 60 mg.
Sourced from GMP-certified and ISO-compliant manufacturers, this API meets
global pharmacopeia standards (USP/EP/JP as applicable). Ideal for pharmaceutical
formulation and commercial manufacturing, Edoxaban is supplied in
bulk quantities with complete regulatory support including DMF, COA, and MSDS.
|
Technical Specifications & Supply Details
|
| Lead Time |
7 to 60 days (depending on batch size & schedule) |
| MOQ |
As per manufacturer’s batch size |
| COA |
Available with every batch |
| Regulatory Dossier / DMF |
Available upon request |
| Export Documentation |
FSC, COA, Manufacturing License, Product Permission |
| Standards |
IP, BP, USP |
| Certifications |
WHO-GMP, EU-GMP, USFDA (as applicable) |
Edoxaban can be exported to over 30 countries across Asia, Africa, Europe,
and Latin America. Flexible packaging, competitive pricing, and a verified supplier
network make Pharmatradz a trusted sourcing partner for pharmaceutical companies
and contract manufacturers worldwide.
Product Description:
Edoxaban is an oral anticoagulant medication and a selective direct factor Xa inhibitor used to prevent and treat thromboembolic disorders. It works by inhibiting factor Xa, a key enzyme in the coagulation cascade, thereby reducing thrombin generation and preventing the formation of blood clots. Edoxaban is administered orally and is well-established for long-term anticoagulation therapy.
In the United States, edoxaban is approved for the treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE) following an initial 5 to 10 days of therapy with a parenteral anticoagulant. It is also indicated to reduce the risk of stroke and systemic embolism in patients with non-valvular atrial fibrillation.
In the European Union, edoxaban is indicated for the prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation who have one or more risk factors, including previous stroke, hypertension, diabetes mellitus, congestive heart failure, or age 75 years or older. Additionally, it is used for the treatment of DVT and PE and for the prevention of their recurrence.
Disclaimer: By continuing to browse, you agree to the terms of use of this website and the Trade Marks displayed, in compliance with the provisions of the Trademark Act, 1999, Section 30 and 30(1) under 'Fair use.'
The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Back to Listing